Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Testing Status of Dicyclohexylcarbodiimide M930062

 

CASRN: 538-75-0

Formula: C13-H22-N2

Synonyms/Common Names

  • Bis(cyclohexyl)carbodiimide
  • DCC

Short-Term Toxicity

  • 2 weeks (Topical Application)  (C93021)  Completed 
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R&M: 0, 2, 6, 17, 50, OR 150 MG/ML; 5/SEX/SPECIES/GROUP.
  • 13 weeks (Topical Application)  (C93021)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG M: 0, 1.5, 3, 6, 12, OR 24 MG/KG; 10/SEX/SPECIES/GROUP; 6 GROUPS.
  • 20 weeks (Topical Application)  (C93021B)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: Tg.AC (FVB/N) Hemizygous
    • Dose: FEMALE MICE: 0, 0.75, 1.5, 3, 6, 12 MG/KG; 10/GROUP.
  • 27 weeks (Topical Application)  (C93021C)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: P53 +/- (C57BL/6)
    • Carcinogenesis Results
      • Female No Evidence 
    • Dose: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG; 15/GROUP.

Special Studies

  • Absorption Distribution Metabolism Excretion (Intravenous; Topical Application; Intravenous; Topical Application)  (S0663)  Completed 
    • Male Rats: F344/N; Male Mice: B6C3F1
    • Dose: 0.3, 3 mg/kg, indwelling jugular cannula. 0.3, 3 mg/kg, protective appliance used. 0.4, 0.6 mg/kg, lateral tail vein. 0.7, 6.2 mg/kg.

Genetic Toxicology

  • Micronucleus  (A45449)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Rats: Fischer 344
    • Male Negative 
  • Micronucleus  (A63966)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Mice: B6C3F1
    • Male Weakly Positive 
    • Female Weakly Positive 
  • Salmonella  (A46724)  Completed 
    •  Negative 

Organ Systems Toxicity

  • 4 days, 6 days, 8 days Immunotoxicity (Topical Application)  (IMM96015)  Completed 
    • Female Mice: B6C3F1
    • Dose: 0, .003, .006, .03, & .06% IN ACETONE (99.8%) FOR SENSITIZATION, & .1% FOR CHALLENGE IN THE MEST & .006, .03, .06, AND .1% FOR SENSITIZATION IN THE LLNA. 25% DNFB WAS USED AS THE POSITIVE CONTROL FOR SENSITIZATION, & .5% FOR CHALLENGE.